{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T12:45:10Z","timestamp":1788439510523,"version":"build-2803163510"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:00:00Z","timestamp":1780444800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Currently, epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) represent the standard first-line treatment for advanced EGFR-mutated non-small cell lung cancer (NSCLC). However, as the disease progresses, targeted resistance inevitably develops. Chemoimmunotherapy, as the standard treatment for advanced NSCLC without driver gene mutations, has significantly improved patient survival. EGFR-mutant tumors exhibit unique immunogenicity compared to wild-type tumors, with heterogeneity in programmed death ligand 1(PD-L1) expression levels, tumor mutational burden (TMB), and other immune microenvironment characteristics. Therefore, we elucidate the mechanisms of immune resistance in EGFR-mutant patients and analyze the core immune mechanisms underlying EGFR-TKI resistance. We summarize the application of immune checkpoint inhibitors (ICIs) in advanced EGFR-mutant NSCLC and analyze the associated mechanisms of action.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1845547","type":"journal-article","created":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:37Z","timestamp":1780466737000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and mechanisms of immune checkpoint inhibitors in late-stage EGFR-mutated non-small cell lung cancer following targeted therapy resistance"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiling","family":"Niu","sequence":"first","affiliation":[{"name":"Department of First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]},{"name":"Department of Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Jing","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongkai","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunxuan","family":"Si","sequence":"additional","affiliation":[{"name":"Department of Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaidong","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of First Clinical Medical College, Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]},{"name":"Department of Oncology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine","place":["Jinan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,3]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00798-3","article-title":"The global burden of lung cancer: current status and future trends","volume":"20","author":"Leiter","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12587","article-title":"The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/lctt.s40817","article-title":"Prevalence of driver mutations in non-small-cell lung cancers in the People's Republic of China","volume":"5","author":"Gou","year":"2014","journal-title":"Lung Cancer (Auckl)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/jto.0000000000000033","article-title":"A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER)","volume":"9","author":"Shi","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5549","article-title":"Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70393-x","article-title":"Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial","volume":"13","author":"Rosell","year":"2012","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/bjc.2013.721","article-title":"First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study","volume":"110","author":"Douillard","year":"2014","journal-title":"Br J Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds214","article-title":"Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naive non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002)","volume":"24","author":"Inoue","year":"2013","journal-title":"Ann Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(11)70184-x","article-title":"Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study","volume":"12","author":"Zhou","year":"2011","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx359","article-title":"First-line icotinib versus cisplatin\/pemetrexed plus pemetrexed maintenance therapy for patients with advanced mutation-positive lung adenocarcinoma (CONVINCE): a phase 3, open-label, randomized study","volume":"28","author":"Shi","year":"2017","journal-title":"Ann Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/cas.12723","article-title":"Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3","volume":"106","author":"Kato","year":"2015","journal-title":"Cancer Sci"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(17)30608-3","article-title":"Dacomitinib versus gefitinib as first-line treatment for patients with mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial","volume":"18","author":"Wu","year":"2017","journal-title":"Lancet Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.02641","article-title":"AENEAS: A randomized phase III trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastatic non-small-cell lung cancer with EGFR exon 19 deletion or L858R mutations","volume":"40","author":"Lu","year":"2022","journal-title":"J Clin Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00183-2","article-title":"Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Resp Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(22)00168-0","article-title":"Furmonertinib (AST2818) versus gefitinib as first-line therapy for Chinese patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (FURLONG): a multicentre, double-blind, randomised phase 3 study","volume":"10","author":"Shi","year":"2022","journal-title":"Lancet Respir Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.05.011","article-title":"Efficacy and safety of limertinib (ASK120067) in patients with locally advanced or metastatic EGFR Thr790Met-mutated NSCLC: a multicenter, single-arm, phase 2b study","volume":"17","author":"Shi","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-021-00794-6","article-title":"Osimertinib versus comparator EGFR TKI as first-line treatment for EGFR-mutated advanced NSCLC: FLAURA China, a randomized study","volume":"16","author":"Cheng","year":"2021","journal-title":"Targ Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-13-2233","article-title":"The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial","volume":"20","author":"Costa","year":"2014","journal-title":"Clin Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa0909530","article-title":"Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"362","author":"Maemondo","year":"2010","journal-title":"N Engl J Med"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02547","article-title":"Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations","volume":"31","author":"Sequist","year":"2013","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02747","article-title":"Phase III KEYNOTE-789 study of pemetrexed and platinum with or without pembrolizumab for tyrosine kinase inhibitor\u2013resistant, EGFR-mutant, metastatic nonsquamous non-small cell lung cancer","volume":"42","author":"Yang","year":"2024","journal-title":"J Clin Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(15)00121-7","article-title":"Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial","volume":"16","author":"Soria","year":"2015","journal-title":"Lancet Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2017.07.107","article-title":"Continuation of gefitinib plus chemotherapy prolongs progression-free survival in advanced non-small cell lung cancer patients who get acquired resistance to gefitinib without T790M mutations","volume":"9","author":"Ding","year":"2017","journal-title":"J Thorac Dis"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.73.9250","article-title":"Gefitinib plus chemotherapy versus chemotherapy in epidermal growth factor receptor mutation-positive non-small-cell lung cancer resistant to first-line gefitinib (IMPRESS): overall survival and biomarker analyses","volume":"35","author":"Mok","year":"2017","journal-title":"J Clin Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2014.12.007","article-title":"A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109)","volume":"87","author":"Hattori","year":"2015","journal-title":"Lung Cancer"},{"key":"B28","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1186\/s12890-023-02705-z","article-title":"A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC","volume":"23","author":"Han","year":"2023","journal-title":"BMC Pulm Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.01.006","article-title":"Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial","volume":"14","author":"Wu","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(23)00774-2","article-title":"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study","volume":"402","author":"Lee","year":"2023","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.09.015","article-title":"Long-term overall survival from KEYNOTE-021 cohort G: pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced nonsquamous NSCLC","volume":"16","author":"Awad","year":"2021","journal-title":"J Thorac Oncol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lungcan.2022.07.013","article-title":"Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study","volume":"171","author":"Zhang","year":"2022","journal-title":"Lung Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12229","article-title":"The efficacy and possible mechanisms of immune checkpoint inhibitors in treating non-small cell lung cancer patients with epidermal growth factor receptor mutation","volume":"41","author":"Ma","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B34","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1186\/s12964-022-00958-5","article-title":"ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production","volume":"20","author":"Sun","year":"2022","journal-title":"Cell Commun Signal"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-21-0751","article-title":"CD8+ T-cell responses are boosted by dual PD-1\/VEGFR2 blockade after EGFR inhibition in EGFR-mutant lung cancer","volume":"10","author":"Nishii","year":"2022","journal-title":"Cancer Immunol Res"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2024.03.019","article-title":"EGFR oncogenic mutations in NSCLC impair macrophage phagocytosis and mediate innate immune evasion through up-regulation of CD47","volume":"19","author":"Hu","year":"2024","journal-title":"J Thorac Oncol"},{"key":"B37","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1186\/s12967-024-05110-0","article-title":"Lack of shared neoantigens in prevalent mutations in cancer","volume":"22","author":"Ragone","year":"2024","journal-title":"J Transl Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcpro.2021.100136","article-title":"Proteogenomic analysis unveils the HLA class I-presented immunopeptidome in melanoma and EGFR-mutant lung adenocarcinoma","volume":"20","author":"Qi","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"B39","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-024-07327-9","article-title":"Targeting EGFR-binding protein SLC7A11 enhancing antitumor immunity of T cells via inducing MHC-I antigen presentation in nasopharyngeal carcinoma","volume":"16","author":"Wang","year":"2025","journal-title":"Cell Death Dis"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2310821121","article-title":"Targeted demethylation and activation of NLRC5 augment cancer immunogenicity through MHC class I","volume":"121","author":"Sun","year":"2024","journal-title":"Proc Natl Acad Sci USA"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1512509","article-title":"The role of B2M in cancer immunotherapy resistance: function, resistance mechanism, and reversal strategies","volume":"16","author":"Han","year":"2025","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.canlet.2021.06.008","article-title":"Beta2-microglobulin(B2M) in cancer immunotherapies: biological function, resistance and remedy","volume":"517","author":"Wang","year":"2021","journal-title":"Cancer Lett"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.modpat.2025.100899","article-title":"Loss of ribosomal protein L22 (RPL22) expression identifies a transcriptional subset of MLH1-deficient endometrial cancers with lower numbers of tumor-associated lymphocytes","volume":"39","author":"Osborne-Frazier","year":"2026","journal-title":"Mod Pathol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4958","DOI":"10.1038\/s41467-025-60281-8","article-title":"TEIPP-vaccination in checkpoint-resistant non-small cell lung cancer: a first-in-human phase I\/II dose-escalation study","volume":"16","author":"Emmers","year":"2025","journal-title":"Nat Commun"},{"key":"B45","doi-asserted-by":"publisher","first-page":"eaav3937","DOI":"10.1126\/sciimmunol.aav3937","article-title":"Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer","volume":"5","author":"Sugiyama","year":"2020","journal-title":"Sci Immunol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12943-019-1062-7","article-title":"Role of the dynamic tumor microenvironment in controversies regarding immune checkpoint inhibitors for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations","volume":"18","author":"Lin","year":"2019","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202513182","article-title":"Overcoming EGFR-mediated dendritic cell dysfunction to enhance anti-tumor immunity in EGFR-mutant NSCLC by precisely targeting CD73 with pH-responsive nanocarriers","volume":"13","author":"Shang","year":"2026","journal-title":"Adv Sci (Weinh)"},{"key":"B48","doi-asserted-by":"publisher","first-page":"6068","DOI":"10.1038\/s41467-021-26362-0","article-title":"Dysregulation of T(FH)-B-T(RM) lymphocyte cooperation is associated with unfavorable anti-PD-1 responses in EGFR-mutant lung cancer","volume":"12","author":"Cho","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-025-03318-y","article-title":"Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1\/glycolysis\/H3K18la positive feedback loop","volume":"44","author":"Zhang","year":"2025","journal-title":"Oncogene"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.can-25-0433","article-title":"Transfer of damaged mitochondria from cancer cells to cancer-associated fibroblasts promotes tyrosine kinase inhibitor tolerance in EGFR-mutant lung cancer","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1101\/2022.04.03.486884","article-title":"T cell-mediated development of stromal fibroblasts with an immune-enhancing chemokine profile","volume":"11","author":"Yan","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B52","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12951-025-03476-x","article-title":"CXCL12-targeting siRNA nanoparticles alleviate immunosuppression and inhibit tumor progression in esophageal squamous cell carcinoma","volume":"23","author":"Zhang","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2025.189520","article-title":"Targeting the tumor immune microenvironment in chordoma: from mechanistic insights to therapeutic breakthroughs","volume":"1881","author":"Zhang","year":"2026","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1235884","article-title":"The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition","volume":"14","author":"Van Dorp","year":"2023","journal-title":"Front Immunol"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-021-01259-5","article-title":"Cancer-associated fibroblasts-derived HAPLN1 promotes tumour invasion through extracellular matrix remodeling in gastric cancer","volume":"25","author":"Zhang","year":"2022","journal-title":"Gastric Cancer"},{"key":"B56","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13045-022-01304-5","article-title":"Crosstalk among m(6)A RNA methylation, hypoxia and metabolic reprogramming in TME: from immunosuppressive microenvironment to clinical application","volume":"15","author":"Zhang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B57","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1038\/s41392-025-02242-7","article-title":"Therapeutic potential of tumor-associated neutrophils: dual role and phenotypic plasticity","volume":"10","author":"Zhou","year":"2025","journal-title":"Signal Transd Targ Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00846-y","article-title":"Myeloid-derived suppressor cells in cancer and cancer therapy","volume":"21","author":"Lasser","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.07.016","article-title":"Strong programmed death ligand 1 expression predicts poor response and de novo resistance to EGFR tyrosine kinase inhibitors among NSCLC patients with EGFR mutation","volume":"13","author":"Su","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-20-893","article-title":"Programmed death-ligand 1 expression level as a predictor of EGFR tyrosine kinase inhibitor efficacy in lung adenocarcinoma","volume":"10","author":"Kang","year":"2021","journal-title":"Transl Lung Cancer R"},{"key":"B61","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.lungcan.2021.03.004","article-title":"Relationship between PD-L1 expression and outcome in EGFR-mutant lung cancer patients treated with EGFR tyrosine kinase inhibitors","volume":"155","author":"Liu","year":"2021","journal-title":"Lung Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"9753","DOI":"10.1038\/s41598-022-13102-7","article-title":"PD-L1 strong expressions affect the clinical outcomes of osimertinib in treatment na\u00efve advanced EGFR-mutant non-small cell lung cancer patients","volume":"12","author":"Hsu","year":"2022","journal-title":"Sci Rep"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-21-461","article-title":"Impact of tumor programmed death ligand-1 expression on osimertinib efficacy in untreated EGFR-mutated advanced non-small cell lung cancer: a prospective observational study","volume":"10","author":"Yoshimura","year":"2021","journal-title":"Transl Lung Cancer R"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2024.2385290","article-title":"Strong PD-L1 affect clinical outcomes in advanced NSCLC treated with third-generation EGFR-TKIs","volume":"20","author":"Niu","year":"2024","journal-title":"Future Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2026.101109","article-title":"Comprehensive clinical characteristics and outcomes of stage IV EGFR-mutant NSCLC based on PD-L1 expression","volume":"46","author":"Lee","year":"2026","journal-title":"Cancer Treat Res Commun"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/7694202","article-title":"Increased EGFR phosphorylation correlates with higher programmed death ligand-1 expression: analysis of TKI-resistant lung cancer cell lines","volume":"2017","author":"Suda","year":"2017","journal-title":"BioMed Res Int"},{"key":"B67","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1186\/s12943-019-1073-4","article-title":"EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression","volume":"18","author":"Peng","year":"2019","journal-title":"Mol Cancer"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-2027","article-title":"Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation-positive non-small cell lung cancer","volume":"26","author":"Isomoto","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.09.012","article-title":"Overcoming tyrosine kinase inhibitor resistance in lung cancer brain metastasis with CTLA4 blockade","volume":"42","author":"Fu","year":"2024","journal-title":"Cancer Cell"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1151748","article-title":"Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands","volume":"14","author":"Garman","year":"2023","journal-title":"Front Immunol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.07.016","article-title":"LAG-3 and PD-1 synergize on CD8(+) T cells to drive T cell exhaustion and hinder autocrine IFN-gamma-dependent anti-tumor immunity","volume":"187","author":"Andrews","year":"2024","journal-title":"Cell"},{"key":"B72","doi-asserted-by":"publisher","first-page":"e194377","DOI":"10.1172\/JCI194377","article-title":"EGFR activation disrupts immunotherapy response via SHP2-mediated suppression of tumor-intrinsic response to IFN-\u03b3","volume":"136","author":"Zhuang","year":"2026","journal-title":"J Clin Invest"},{"key":"B73","doi-asserted-by":"publisher","first-page":"856","DOI":"10.3390\/cells12060856","article-title":"Circulating Melanoma Cell Numbers Correlate with TIGIT-Positive Cytotoxic T Cell Counts in Advanced-Stage Melanoma Patients","volume":"12","author":"Kami\u0144ska","year":"2023","journal-title":"Cells"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1499663","article-title":"Revealing the mechanisms and therapeutic potential of immune checkpoint proteins across diverse protein families","volume":"16","author":"Liu","year":"2025","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-1102","article-title":"Tumor mutation burden and efficacy of EGFR-tyrosine kinase inhibitors in patients with EGFR-mutant lung cancers","volume":"25","author":"Offin","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2025.105877","article-title":"Genomic profiling of high tumor mutational load in microsatellite-stable colorectal cancer uncovers MAPK signaling pathway alterations following anti-EGFR therapy","volume":"10","author":"Boscolo Bielo","year":"2025","journal-title":"ESMO Open"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.00364","article-title":"Circulating tumor DNA identifies diverse landscape of acquired resistance to anti-epidermal growth factor receptor therapy in metastatic colorectal cancer","volume":"41","author":"Topham","year":"2023","journal-title":"J Clin Oncol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-024-00932-9","article-title":"Tumour mutational burden: clinical utility, challenges and emerging improvements","volume":"21","author":"Budczies","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B79","doi-asserted-by":"publisher","first-page":"283","DOI":"10.3390\/life15020283","article-title":"Towards the Prediction of Responses to Cancer Immunotherapy: A Multi-Omics Review","volume":"15","author":"Tao","year":"2025","journal-title":"Life (Basel)"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2022.1981","article-title":"Association of high tumor mutation burden in non-small cell lung cancers with increased immune infiltration and improved clinical outcomes of PD-L1 blockade across PD-L1 expression levels","volume":"8","author":"Ricciuti","year":"2022","journal-title":"JAMA Oncol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz141","article-title":"EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer","volume":"30","author":"Hastings","year":"2019","journal-title":"Ann Oncol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2021.11.006","article-title":"Therapeutic guidance of tumor mutation burden on immune checkpoint inhibitors in advanced non-small cell lung cancer: a systematic review and comprehensive meta-analysis","volume":"2","author":"Zhao","year":"2022","journal-title":"J Natl Cancer Cent"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.01.011","article-title":"Associations of tissue tumor mutational burden and mutational status with clinical outcomes in KEYNOTE-042: pembrolizumab versus chemotherapy for advanced PD-L1-positive NSCLC","volume":"34","author":"Mok","year":"2023","journal-title":"Ann Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02808-y","article-title":"Biomarker-directed targeted therapy plus durvalumab in advanced non-small-cell lung cancer: a phase 2 umbrella trial","volume":"30","author":"Besse","year":"2024","journal-title":"Nat Med"},{"key":"B85","doi-asserted-by":"publisher","first-page":"e003091","DOI":"10.1136\/jitc-2021-003091","article-title":"Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors","volume":"10","author":"Cristescu","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.09.005","article-title":"Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs","volume":"113","author":"Lee","year":"2017","journal-title":"Lung Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1094764","article-title":"Changes of tumor microenvironment in non-small cell lung cancer after TKI treatments","volume":"14","author":"Chen","year":"2023","journal-title":"Front Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1209947","article-title":"Tumor-associated macrophages mediate resistance of EGFR-TKIs in non-small cell lung cancer: mechanisms and prospects","volume":"14","author":"Cheng","year":"2023","journal-title":"Front Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-02945-2","article-title":"RNA methylation of CD47 mediates tumor immunosuppression in EGFR-TKI resistant NSCLC","volume":"132","author":"Zhang","year":"2025","journal-title":"Br J Cancer"},{"key":"B90","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12964-023-01424-6","article-title":"Macrophage barrier in the tumor microenvironment and potential clinical applications","volume":"22","author":"Ji","year":"2024","journal-title":"Cell Commun Signal"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2023.122463","article-title":"Nano-enhanced immunotherapy: targeting the immunosuppressive tumor microenvironment","volume":"305","author":"Jin","year":"2024","journal-title":"Biomaterials"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1093\/nsr\/nwae392","article-title":"Integrative study of lung cancer adeno-to-squamous transition in EGFR TKI resistance identifies RAPGEF3 as a therapeutic target","volume":"11","author":"Wang","year":"2024","journal-title":"Natl Sci Rev"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-22-3379","article-title":"IL6 mediates suppression of T- and NK-cell function in EMT-associated TKI-resistant EGFR-mutant NSCLC","volume":"29","author":"Patel","year":"2023","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1038\/s41467-024-47606-9","article-title":"Mixed responses to targeted therapy driven by chromosomal instability through p53 dysfunction and genome doubling","volume":"15","author":"Hobor","year":"2024","journal-title":"Nat Commun"},{"key":"B95","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/s41698-022-00325-0","article-title":"Landscape of potentially targetable receptor tyrosine kinase fusions in diverse cancers by DNA-based profiling","volume":"6","author":"Wang","year":"2022","journal-title":"NPJ Precis Oncol"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfma.2024.12.020","article-title":"PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: a translational study","volume":"125","author":"Yang","year":"2026","journal-title":"J Formos Med Assoc"},{"key":"B97","doi-asserted-by":"publisher","first-page":"470","DOI":"10.3390\/biomedicines13020470","article-title":"Targeting the Tumor Microenvironment in EGFR-Mutant Lung Cancer: Opportunities and Challenges","volume":"13","author":"Lim","year":"2025","journal-title":"Biomedicines"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1651248","article-title":"Case report: a small cell lung cancer transformed from an EGFR-mutated adenocarcinoma demonstrated a long-term remission to anti PD-1 antibody","volume":"15","author":"Kawanaka","year":"2025","journal-title":"Front Oncol"},{"key":"B99","doi-asserted-by":"publisher","first-page":"e312","DOI":"10.1016\/j.cllc.2024.04.016","article-title":"Brief report: the immune profiles of the molecular subtypes of EGFR-mutant lung adenocarcinomas in a large real-world cohort","volume":"25","author":"Bodor","year":"2024","journal-title":"Clin Lung Cancer"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.15021","article-title":"Influence of PD-L1 expression on the efficacy of EGFR-TKIs in EGFR-mutant non-small cell lung cancer","volume":"14","author":"Lei","year":"2023","journal-title":"Thorac Cancer"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.09.012","article-title":"Immune marker profiling and programmed death ligand 1 expression across NSCLC mutations","volume":"13","author":"Toki","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B102","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s43556-025-00331-1","article-title":"Distinct survival, optimal combination strategy of immunotherapy, and immunophenotype in uncommon and 20ins EGFR-mut lung adenocarcinoma: a multi-center study","volume":"6","author":"Sun","year":"2025","journal-title":"Mol BioMed"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.03.035","article-title":"A phase II study of pembrolizumab in EGFR-mutant, PD-L1+, tyrosine kinase inhibitor naive patients with advanced NSCLC","volume":"13","author":"Lisberg","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.00934","article-title":"Five-year overall survival for patients with advanced non\u2013small-cell lung cancer treated with pembrolizumab: Results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J Clin Oncol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.9929","article-title":"Nivolumab monotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Gettinger","year":"2016","journal-title":"J Clin Oncol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(16)32517-x","article-title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial","volume":"389","author":"Rittmeyer","year":"2017","journal-title":"Lancet"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.10.007","article-title":"Checkpoint inhibitors in metastatic EGFR-mutated non-small cell lung cancer-a meta-analysis","volume":"12","author":"Lee","year":"2017","journal-title":"J Thorac Oncol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2017.4427","article-title":"Clinical and molecular characteristics associated with survival among patients treated with checkpoint inhibitors for advanced non-small cell lung carcinoma: a systematic review and meta-analysis","volume":"4","author":"Lee","year":"2018","journal-title":"JAMA Oncol"},{"key":"B111","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1158\/1078-0432.CCR-21-3194","article-title":"A randomized phase II study comparing nivolumab with carboplatin-pemetrexed for EGFR-mutated NSCLC with resistance to EGFR tyrosine kinase inhibitors (WJOG8515L)","volume":"28","author":"Hayashi","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100388","article-title":"A real-world analysis of immune checkpoint inhibitor-based therapy after osimertinib treatment in patients with EGFR-mutant NSCLC","volume":"3","author":"Morimoto","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(18)30144-x","article-title":"Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study","volume":"19","author":"Garassino","year":"2018","journal-title":"Lancet Oncol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"653","DOI":"10.1186\/s12967-024-05456-5","article-title":"EGFR mutations induce the suppression of CD8(+) T cell and anti-PD-1 resistance via ERK1\/2-p90RSK-TGF-beta axis in non-small cell lung cancer","volume":"22","author":"Huang","year":"2024","journal-title":"J Transl Med"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.11.028","article-title":"Pembrolizumab in combination with erlotinib or gefitinib as first-line therapy for advanced NSCLC with sensitizing EGFR mutation","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab plus erlotinib in patients with mutant advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.02.001","article-title":"Osimertinib plus durvalumab versus osimertinib monotherapy in EGFR T790M-positive NSCLC following previous EGFR TKI therapy: CAURAL brief report","volume":"14","author":"Yang","year":"2019","journal-title":"J Thorac Oncol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2022.01.012","article-title":"Osimertinib plus durvalumab in patients with EGFR-mutated, advanced NSCLC: a phase 1b, open-label, multicenter trial","volume":"17","author":"Ahn","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01099-7","article-title":"A phase 1 study of gefitinib combined with durvalumab in EGFR TKI-naive patients with EGFR mutation-positive locally advanced\/metastatic non-small-cell lung cancer","volume":"124","author":"Creelan","year":"2021","journal-title":"Br J Cancer"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2022.100367","article-title":"Brief report: Safety and antitumor activity of alectinib plus atezolizumab from a phase 1b study in advanced ALK-positive NSCLC","volume":"3","author":"Kim","year":"2022","journal-title":"JTO Clin Res Rep"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.02.022","article-title":"Phase 1\/2 study of the safety and tolerability of nivolumab plus crizotinib for the first-line treatment of anaplastic lymphoma kinase translocation - positive advanced non-small cell lung cancer (CheckMate 370)","volume":"13","author":"Spigel","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00333-8","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis","volume":"22","author":"Zhou","year":"2021","journal-title":"Lancet Oncol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.66.9861","article-title":"Nivolumab in combination with platinum-based doublet chemotherapy for first-line treatment of advanced non-small-cell lung cancer","volume":"34","author":"Rizvi","year":"2016","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(19)30167-6","article-title":"Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"West","year":"2019","journal-title":"Lancet Oncol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01017","article-title":"Nivolumab plus chemotherapy in epidermal growth factor receptor-mutated metastatic non-small-cell lung cancer after disease progression on epidermal growth factor receptor tyrosine kinase inhibitors: final results of CheckMate 722","volume":"42","author":"Mok","year":"2024","journal-title":"J Clin Oncol"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.02.022","article-title":"Durvalumab plus chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis","volume":"33","author":"Cho","year":"2022","journal-title":"Ann Oncol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.cir-16-0197","article-title":"Immunological mechanisms underneath the efficacy of cancer therapy","volume":"4","author":"Galluzzi","year":"2016","journal-title":"Cancer Immunol Res"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2021.09.014","article-title":"IMpower150 final exploratory analyses for atezolizumab plus bevacizumab and chemotherapy in key NSCLC patient subgroups with EGFR mutations or metastases in the liver or brain","volume":"17","author":"Nogami","year":"2022","journal-title":"J Thorac Oncol"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.113469","article-title":"A phase II study of atezolizumab with bevacizumab, carboplatin, and paclitaxel for patients with EGFR-mutated NSCLC after TKI treatment failure (NEJ043 study)","volume":"197","author":"Watanabe","year":"2024","journal-title":"Eur J Cancer"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107843","article-title":"Safety and patient-reported outcomes of atezolizumab plus chemotherapy with or without bevacizumab in stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies (GFPC 06-2018 study)","volume":"193","author":"Amari","year":"2024","journal-title":"Lung Cancer"},{"key":"B131","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2023.01.014","article-title":"Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB\/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study GFPC 06-2018","volume":"183","author":"Bylicki","year":"2023","journal-title":"Eur J Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00382-5","article-title":"Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial","volume":"23","author":"Lu","year":"2022","journal-title":"Lancet Oncol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(23)00135-2","article-title":"Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"11","author":"Lu","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.068","article-title":"Phase III, randomized study of atezolizumab plus bevacizumab and chemotherapy in patients with EGFR- or ALK-mutated non-small-cell lung cancer (ATTLAS, KCSG-LU19-04)","volume":"42","author":"Park","year":"2024","journal-title":"J Clin Oncol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1512468","article-title":"Efficacy and safety of immune checkpoint inhibitors for EGFR mutated non-small cell lung cancer: a network meta-analysis","volume":"15","author":"Zhu","year":"2024","journal-title":"Front Immunol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(24)00379-6","article-title":"Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis","volume":"25","author":"Zhao","year":"2024","journal-title":"Lancet Oncol"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71469","article-title":"Efficacy and safety of atezolizumab plus bevacizumab in patients with advanced NSCLC who received pretreatment with EGFR-TKIs (ML41256): a multicenter, prospective, single-arm, phase 2 trial","volume":"14","author":"Fang","year":"2025","journal-title":"Cancer Med"},{"key":"B140","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/s41392-024-01982-2","article-title":"Benmelstobart plus anlotinib in patients with EGFR-positive advanced NSCLC after failure of EGFR TKIs therapy: a phase I\/II study","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transd Targ Ther"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102106","article-title":"AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial","volume":"62","author":"Zhao","year":"2023","journal-title":"EClinicalMedicine"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01731-x","article-title":"QL1706 (anti-PD-1 IgG4\/CTLA-4 antibody) plus chemotherapy with or without bevacizumab in advanced non-small cell lung cancer: a multi-cohort, phase II study","volume":"9","author":"Huang","year":"2024","journal-title":"Signal Transd Targ Ther"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.s539675","article-title":"Immunotherapy rechallenge of advanced NSCLC with acquired EGFR T790M mutation after EGFR-TKI therapy: a case report","volume":"17","author":"Hu","year":"2025","journal-title":"Cancer Manag Res"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2025.07.129","article-title":"Final analysis results and patient-reported outcomes from DESTINY-Lung02-a dose-blinded, randomized, phase 2 study of trastuzumab deruxtecan in patients with HER2-mutant metastatic NSCLC","volume":"20","author":"J\u00e4nne","year":"2025","journal-title":"J Thorac Oncol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1200\/jco-24-01349","article-title":"Datopotamab deruxtecan in advanced or metastatic non-small cell lung cancer with actionable genomic alterations: results from the phase II TROPION-Lung05 study","volume":"43","author":"Sands","year":"2025","journal-title":"J Clin Oncol"},{"key":"B146","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1056\/NEJMoa2512071","article-title":"Sacituzumab tirumotecan in EGFR-TKI-resistant, EGFR-mutated advanced NSCLC","volume":"394","author":"Fang","year":"2026","journal-title":"N Engl J Med"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01476","article-title":"HERTHENA-Lung01, a phase II trial of patritumab deruxtecan (HER3-DXd) in epidermal growth factor receptor-mutated non-small-cell lung cancer after epidermal growth factor receptor tyrosine kinase inhibitor therapy and platinum-based chemotherapy","volume":"41","author":"Yu","year":"2023","journal-title":"J Clin Oncol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1495675","article-title":"Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: mechanisms, clinical applications, and future directions","volume":"15","author":"Tong","year":"2024","journal-title":"Front Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2220466","article-title":"A HER2-targeted antibody-novel DNA topoisomerase I inhibitor conjugate induces durable adaptive antitumor immunity by activating dendritic cells","volume":"15","author":"Tan","year":"2023","journal-title":"MAbs"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2025.2533488","article-title":"Immunogenic cell death and bystander killing: expanding the therapeutic potential of modern antibody-drug conjugates","volume":"14","author":"Kepp","year":"2025","journal-title":"Oncoimmunology"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1632705","article-title":"Another power of antibody-drug conjugates: immunomodulatory effect and clinical applications","volume":"16","author":"Shi","year":"2025","journal-title":"Front Immunol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1678907","article-title":"Antibody-drug conjugates as immuno-oncology agents in colorectal cancer: targets, payloads, and therapeutic synergies","volume":"16","author":"Wang","year":"2025","journal-title":"Front Immunol"},{"key":"B153","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.jconrel.2023.05.031","article-title":"Immune checkpoint-targeted drug conjugates: a promising tool for remodeling tumor immune microenvironment","volume":"359","author":"Choi","year":"2023","journal-title":"J Ctrl Rel"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy446.009","article-title":"Radiotherapy with continued EGFR-TKIs for oligoprogressive disease in EGFR-mutated non-small cell lung cancer: a real-world study","volume":"12","author":"Hu","year":"2023","journal-title":"Cancer Med"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02075","article-title":"Thoracic radiotherapy improves the survival in patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer treated with epidermal growth factor receptor-tyrosine kinase inhibitors: a multicenter, randomized, controlled, phase III trial","volume":"43","author":"Sun","year":"2025","journal-title":"J Clin Oncol"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2021.07.052","article-title":"Translocator protein-targeted photodynamic therapy for direct and abscopal immunogenic cell death in colorectal cancer","volume":"134","author":"Xie","year":"2021","journal-title":"Acta Biomater"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213222","article-title":"Neoadjuvant SBRT combined with immunotherapy in NSCLC: from mechanisms to therapy","volume":"14","author":"Shi","year":"2023","journal-title":"Front Immunol"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1139527","article-title":"Abscopal effect triggered by radiation sequential mono-immunotherapy resulted in a complete remission of PMMR sigmoid colon cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Front Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-21-0003","article-title":"Low-dose radiotherapy reverses tumor immune desertification and resistance to immunotherapy","volume":"12","author":"Herrera","year":"2022","journal-title":"Cancer Discov"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1630940","article-title":"Breakthroughs in immune checkpoint therapy: overcoming NSCLC immune checkpoint therapy resistance with novel techniques","volume":"16","author":"Kang","year":"2025","journal-title":"Front Immunol"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejmech.2024.116858","article-title":"Design, synthesis, and biological evaluation of diphenyl ether substituted quinazolin-4-amine derivatives as potent EGFR(L858R\/T790M\/C797S) inhibitors","volume":"279","author":"Dou","year":"2024","journal-title":"Eur J Med Chem"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1016\/j.jare.2024.10.008","article-title":"Applications of single-cell analysis in immunotherapy for lung cancer: current progress, new challenges and expectations","volume":"74","author":"Xiao","year":"2025","journal-title":"J Adv Res"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.05.015","article-title":"Nivolumab plus erlotinib in patients with EGFR-mutant advanced NSCLC","volume":"13","author":"Gettinger","year":"2018","journal-title":"J Thorac Oncol"},{"key":"B164","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1038\/s41392-021-00751-9","article-title":"Toripalimab plus chemotherapy as second-line treatment in previously EGFR-TKI treated patients with EGFR-mutant-advanced NSCLC: a multicenter phase-II trial","volume":"6","author":"Jiang","year":"2021","journal-title":"Signal Transd Targ Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1158\/2326-6066.cir-22-0815","article-title":"High expression of MHC class I overcomes cancer immunotherapy resistance due to IFNgamma signaling pathway defects","volume":"11","author":"Kawase","year":"2023","journal-title":"Cancer Immunol Res"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2023.07.020","article-title":"STK11\/LKB1-deficient phenotype rather than mutation diminishes immunotherapy efficacy and represents STING\/type I interferon\/CD8(+) T-cell dysfunction in NSCLC","volume":"18","author":"Li","year":"2023","journal-title":"J Thorac Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.113295","article-title":"KEAP1 mutation in lung adenocarcinoma promotes immune evasion and immunotherapy resistance","volume":"42","author":"Zavitsanou","year":"2023","journal-title":"Cell Rep"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2023.04.005","article-title":"ARID1A mutations in lung cancer: biology, prognostic role, and therapeutic implications","volume":"29","author":"Jin","year":"2023","journal-title":"Trends Mol Med"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.12.002","article-title":"Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma","volume":"34","author":"Scalera","year":"2023","journal-title":"Ann Oncol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103660","article-title":"Chemotherapy and programmed cell death protein 1\/programmed death-ligand 1 inhibitor combinations for tyrosine kinase inhibitor-resistant, epidermal growth factor receptor-mutated non-small-cell lung cancer: a meta-analysis","volume":"9","author":"Piotrowska","year":"2024","journal-title":"ESMO Open"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awab012","article-title":"Emerging principles of brain immunology and immune checkpoint blockade in brain metastases","volume":"144","author":"Fares","year":"2021","journal-title":"Brain"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1016\/j.jncc.2024.06.004","article-title":"Immunological features of EGFR-mutant non-small cell lung cancer and clinical practice: a narrative review","volume":"4","author":"Dong","year":"2024","journal-title":"J Natl Cancer Cent"},{"key":"B173","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s10238-025-01927-1","article-title":"Loss of CDKN2A enhances the efficacy of immunotherapy in EGFR-mutant non-small cell lung cancer","volume":"85","author":"Wang","year":"2025","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845547\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T06:05:39Z","timestamp":1780466739000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1845547\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,3]]},"references-count":173,"alternative-id":["10.3389\/fimmu.2026.1845547"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1845547","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,3]]},"article-number":"1845547"}}